New Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, CA 92037
September 13, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
| Re: | New Ambrx Biopharma Inc. Registration Statement on Form S-4 File No. 333-274230 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, New Ambrx Biopharma Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 15, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective.
Please contact Raymond Bogenrief, of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at (312) 407-0550, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
| Sincerely, |
| /s/ Daniel J. O’Connor |
| Daniel J. O’Connor |
| President and Chief Executive Officer |
